By Fineline Cube 
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities and CICC acting as joint sponsors. This follows the company’s initial filing in December last year.
Company Overview and Lead Program
Founded in 2014, Innogen Pharma is dedicated to developing innovative therapies for type 2 diabetes (T2D) and other metabolic diseases. Its lead program, efsubaglutide alfa, is the first domestically developed long-acting GLP-1 receptor agonist approved for T2D in China. Commercialized in February 2025, the drug can be administered as monotherapy or in combination with metformin. It is also being evaluated in Phase IIa studies for obesity, overweight, and metabolic dysfunction-associated steatohepatitis (MASH). The company’s pipeline includes five pre-clinical candidate drugs.
Financials and R&D Commitment
In 2024, Innogen Pharma reported R&D expenses of RMB 103 million (USD 14.3 million) and a loss of RMB 175 million (USD 24.3 million). The company is committed to accelerating R&D investment and the commercialization of its pipeline.-Fineline Info & Tech